<code id='F72431CA93'></code><style id='F72431CA93'></style>
    • <acronym id='F72431CA93'></acronym>
      <center id='F72431CA93'><center id='F72431CA93'><tfoot id='F72431CA93'></tfoot></center><abbr id='F72431CA93'><dir id='F72431CA93'><tfoot id='F72431CA93'></tfoot><noframes id='F72431CA93'>

    • <optgroup id='F72431CA93'><strike id='F72431CA93'><sup id='F72431CA93'></sup></strike><code id='F72431CA93'></code></optgroup>
        1. <b id='F72431CA93'><label id='F72431CA93'><select id='F72431CA93'><dt id='F72431CA93'><span id='F72431CA93'></span></dt></select></label></b><u id='F72431CA93'></u>
          <i id='F72431CA93'><strike id='F72431CA93'><tt id='F72431CA93'><pre id='F72431CA93'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:71971
          Adobe

          Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

          As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

          advertisement

          That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more
          FDA grants conditional OK to Sarepta’s gene therapy for Duchenne
          FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

          KristofferTripplaar/SipaviaAPTheFoodandDrugAdministrationgrantedconditionalapprovalThursdaytothefirs

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

          U.S.AgencyforInternationalDevelopmentAdministratorSamanthaPower,left,talkswithUkraine'sfirstladyOlen